6PHASE I STUDY OF MONOCLONAL ANTIBODY FRAGMENT 131I MEL-14 F(AB')2 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY IN THE TREATMENT OF PATIENTS WITH PRIMARY OR METASTATIC MALIGNANT MELANOMA AND OTHER BRAIN TUMORS.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Monoclonal antibody Me1-14 I-131 (Primary)
- Indications Anaplastic astrocytoma; Astrocytoma; Brain cancer; Glioblastoma; Glioma; Gliosarcoma; Malignant melanoma
- Focus Adverse reactions
- 20 Feb 2013 Biomarkers information updated
- 13 Dec 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 10 Sep 2009 Trial phase changed from I/II to I as reported by ClinicalTrials.gov.